AstraZeneca Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
GET THE FULL COMPANY
ANALYSIS BUNDLE FOR
AstraZeneca
Actionable Strategy Starts Here
AstraZeneca’s BCG Matrix preview highlights which therapeutic areas and franchises are acting as Stars, Cash Cows, Question Marks, or Dogs amid rapid biopharma shifts—spotlighting oncology strength and emerging respiratory assets. This snapshot shows where cash generation fuels R&D and where strategic divestment or investment might be needed. Purchase the full BCG Matrix for quadrant-level placements, data-backed recommendations, and ready-to-use Word and Excel deliverables to guide investment and portfolio decisions.
Stars
Enhertu
Enhertu, AstraZeneca’s premier antibody-drug conjugate (ADC), posted explosive 2025 alliance revenue growth of 38% to about $12.6 billion, cementing a Star profile in the BCG matrix.
By late 2025 Enhertu is the standard of care for HER2-positive and HER2-low metastatic breast cancer after new first-line approvals, driving rapid uptake in the US and EU.
Ongoing heavy investment in trials for gastric and lung cancers keeps R&D spend high, matching the high-growth, high-share Star classification and positioning Enhertu as a future cash generator.
Tezspire
Tezspire is a Star in AstraZeneca’s BCG matrix: severe-asthma biologic sales rose 65% to $1.13 billion in 2025, driving high revenue growth and strong market share.
It differentiates by treating a broad patient pool regardless of eosinophil biomarkers, expanding addressable market versus traditional eosinophilic biologics.
However, Tezspire consumes heavy cash for global marketing and reimbursement against incumbents—pressuring margins and free cash flow in 2025.
If US and Japan adoption trends persist, Tezspire is likely to become a Cash Cow as the severe-asthma market matures.
Ultomiris
Ultomiris grew 16% in 2025 to $1.27 billion in quarterly sales after transitioning many patients from Soliris, securing a leading share in PNH and aHUS rare-disease markets.
Classed as a Star, Ultomiris is gaining new indications and entering major markets like China, requiring sustained R&D and promotion to support growth.
Strong patent protection through the 2030s underpins its leadership in AstraZeneca’s rare-disease portfolio and fuels the company’s 2030 revenue targets.
Imfinzi
Imfinzi is AstraZeneca’s Star in the BCG matrix: it drove a 39% revenue jump to $1.75 billion in Q4 2025 and leads the unresectable Stage III non-small cell lung cancer market while rapidly gaining share in perioperative gastric and biliary tract cancers.
High IO (immuno-oncology) segment growth makes Imfinzi a cash-consuming growth leader; AstraZeneca is funding large combo trials to defend and extend label, keeping it the primary driver of the company’s double-digit oncology growth.
- Q4 2025 revenue: $1.75B (+39%)
- Market leader: unresectable Stage III NSCLC
- Fast share gains: perioperative gastric, biliary cancers
- Requires heavy R&D investment in combos
- Key driver of double-digit oncology growth
Breztri
Breztri, AstraZeneca’s triple-therapy COPD inhaler, is a Star: 2025 sales rose 23% to about $1.2 billion, driven by leading fixed-dose combination (FDC) share in China and expanding US/Europe rollout.
It generates strong cash but high launch and pricing pressures keep it in Stars; sustained investment in triple-threat efficacy data is critical to defend versus other respiratory majors.
- 2025 sales ≈ $1.2B
- 2025 growth +23%
- Leading FDC share in China
- High launch costs & pricing pressure
- Ongoing clinical data investment required
Blockbuster lineup: Enhertu, Imfinzi, Tezspire, Ultomiris, Breztri drive strong 2025 growth
Stars: Enhertu $12.6B (2025, +38%) — first-line HER2+/-; Tezspire $1.13B (+65%) — broad severe asthma; Ultomiris $1.27B (+16%) — PNH/aHUS leader; Imfinzi $1.75B (Q4 2025, +39%) — IO growth; Breztri $1.2B (+23%) — COPD FDC China leader.
| Product | 2025 Rev | Growth | Notes |
|---|---|---|---|
| Enhertu | $12.6B | +38% | First-line HER2+/HER2-low |
| Tezspire | $1.13B | +65% | Broad severe asthma |
| Ultomiris | $1.27B | +16% | PNH/aHUS leader |
| Imfinzi | $1.75B (Q4) | +39% | IO combos, perioperative gains |
| Breztri | $1.2B | +23% | COPD FDC, China lead |
What is included in the product
Detailed Word Document
Comprehensive BCG analysis of AstraZeneca’s portfolio: identifies Stars, Cash Cows, Question Marks, Dogs with strategic invest/hold/divest guidance.
Customizable Excel Spreadsheet
One-page AstraZeneca BCG Matrix placing each business unit in a quadrant for swift portfolio decisions.
Cash Cows
Farxiga
Farxiga, AstraZeneca’s leading SGLT2 inhibitor, delivered over $2.06 billion in Q4 2025 with steady high-single-digit growth, making it a top cash cow.
It holds dominant market share in mature T2D, heart failure, and CKD markets, producing a reliable stream of high-margin cash.
Established indications mean lower promotional spend than oncology, freeing free cash flow for R&D and to support AstraZeneca’s 2025 dividend payments.
Tagrisso
Tagrisso remains the backbone of AstraZeneca’s oncology segment, delivering roughly $1.9 billion in Q4 2025 sales as the established leader in EGFR‑mutated non‑small cell lung cancer.
Growth has stabilized at about 10–12% in mature markets, but high market share and lean manufacturing make it a classic Cash Cow.
Its operating margins are among the highest in the portfolio, funding R&D and expansion into cell therapy programs.
Despite impending patent cliffs, Tagrisso’s current dominance lets AstraZeneca milk substantial cash flow for reinvestment.
Lynparza
Lynparza, the first-in-class PARP inhibitor, generated $878 million in Q4 2025 sales and holds a leading share across ovarian, breast, prostate, and pancreatic cancers via AstraZeneca’s Merck partnership.
Growth slowed to 4% as the PARP market matures, but high share and low capex mean most revenue converts to operating profit, keeping Lynparza a cash cow for AstraZeneca’s oncology franchise.
Calquence
Calquence reached $967 million in Q4 2025 sales and grew 20% year-over-year, securing leadership in front-line CLL; its high market share in a stable therapeutic area marks it as a maturing Star shifting into the Cash Cow quadrant.
The drug delivers steady, high-margin cash flow thanks to an established safety-efficacy profile and strong physician loyalty, funding R&D for next-generation hematology assets in AstraZeneca’s pipeline.
- Q4 2025 sales: $967M
- YoY growth: 20%
- Status: maturing Star → Cash Cow
- Role: funds hematology R&D
- Key strength: high margins, physician loyalty
Fasenra
Fasenra is a mature leader in severe eosinophilic asthma, delivering $530 million in Q4 2025 sales and sustaining a 12% growth rate, marking it as a high-share, low-growth product for AstraZeneca.
Its convenient dosing and proven long-term safety keep strong specialist uptake; market saturation makes it a Cash Cow that generates steady free cash flow with optimized marketing spend.
Fasenra’s cash supports launches like Airsupra and expands AstraZeneca’s immunology portfolio, funding R&D and commercialization without large incremental investment.
- Q4 2025 sales $530 million
- 12% steady growth rate
- High specialist market share
- Funds Airsupra launch and immunology expansion
High‑margin cash engines: Farxiga $2.06B, Tagrisso $1.9B fuel R&D & launches
Farxiga $2.06B Q4 2025; Tagrisso $1.9B; Lynparza $878M; Calquence $967M; Fasenra $530M — high-share, low-growth assets generating strong operating margins and free cash flow to fund R&D, dividends, and new launches.
| Product | Q4 2025 Sales | Growth |
|---|---|---|
| Farxiga | $2.06B | high‑single‑digit |
| Tagrisso | $1.9B | 10–12% |
| Lynparza | $878M | ~4% |
| Calquence | $967M | 20% |
| Fasenra | $530M | 12% |
Preview = Final Product
AstraZeneca BCG Matrix
The file you're previewing is the exact AstraZeneca BCG Matrix report you'll receive after purchase—no watermarks, no demo content—just a fully formatted, analysis-ready document crafted for strategic clarity and professional use.
Dogs
Soliris
Soliris sits in AstraZeneca’s BCG Dog quadrant: sales plunged 26% to $401 million in late 2025 due to biosimilar pressure and shrinking demand.
AstraZeneca has strategically cannibalized Soliris with Ultomiris to protect overall complement-inhibitor market share, leaving Soliris in low-growth, low-share status.
The drug now requires minimal investment and is being phased out across many indications, retained mainly to serve a dwindling patient base while resources shift to newer assets.
Pulmicort
Pulmicort saw a 24% sales decline by end-2025, hit by generics and procurement shifts in China, cutting global FY2025 revenue contribution to roughly low-double-digit millions USD.
It sits in a mature, low-growth respiratory market where AstraZeneca lacks molecule-level dominance; market CAGR ~1–2% makes recovery unlikely.
Pulmicort is a cash trap: ongoing maintenance costs but no growth or margin upside, and management has deprioritized it for biologics and triple combos.
Brilinta
Brilinta (ticagrelor) is a legacy AstraZeneca cardiovascular drug that lost exclusivity in key markets by 2025, facing heavy generic pressure; global sales fell to about $450m in 2024 from $1.2bn peak in 2016, reflecting stagnant/declining uptake versus newer anticoagulants.
By 2025 Brilinta sits in the BCG matrix as a Dog: low market share in a low-growth anticoagulant/antiplatelet category, minimal promotional spend, and often reported within 'other' legacy medicines.
Given persistent generic erosion and limited strategic fit, AstraZeneca favors divestiture or passive management; expect continued run-off, with routine supply deals or asset sale as likely outcomes.
Legacy Vaccines
Older vaccine platforms from the early COVID-19 era have seen market share collapse as demand shifted to updated mRNA and next-gen platforms; by end-2025 these legacy products show low demand and high storage/maintenance costs, fitting the Dog profile.
AstraZeneca has pivoted to its Beyfortus (nirsevimab) partnership and mRNA collaborations, leaving older vaccine assets as phase-out candidates; they add negligible revenue to the company’s reported 8% top-line growth in 2025.
- Legacy platforms: steep volume decline vs 2021; market share near-zero
- High fixed cold-chain costs: ~20–30% higher per dose maintenance
- Revenue contribution: <1% of AstraZeneca sales in 2025
Mature CVRM Generics
Mature CVRM Generics: AstraZeneca’s older, off-patent cardiovascular and metabolism drugs show falling revenues—estimated low-single-digit decline y/y in 2024—with minimal pricing power and no market leadership, operating in high-competition, low-margin segments.
They typically break even and do not advance Ambition 2030 targets, so divestment is likely; AZ instead concentrates CVRM investment on Farxiga (2024 sales ~7.4 billion USD) and a new weight-management pipeline.
- Declining revenues, low-single-digit y/y (2024)
- High competition, low margins, no pricing power
- Break-even; not supporting Ambition 2030
- Divestment candidate; focus shifted to Farxiga (~7.4B USD in 2024) and weight-loss pipeline
AstraZeneca’s shrinking legacy: Soliris -26%, Pulmicort -24%, Brilinta falters
AstraZeneca Dogs: Soliris sales down 26% to $401M (late 2025); Pulmicort down 24% (FY2025 low-double‑digit M); Brilinta ~ $450M (2024); legacy vaccines <1% revenue (2025); mature CVRM generics low-single-digit decline (2024). Minimal investment; run-off/divestment likely.
| Asset | Rev | Trend |
|---|---|---|
| Soliris | $401M | -26% (2025) |
| Pulmicort | Low‑$10sM | -24% (2025) |
| Brilinta | $450M | ↓ vs $1.2B peak |
Question Marks
Airsupra
Airsupra, AstraZeneca’s newly launched rescue inhaler, doubled sales in 2025 (over 100% growth) but still holds single-digit share in the $50B US respiratory market, making it a Question Mark.
As the first combination therapy for acute asthma symptoms, it has high upside yet needs heavy marketing and field rep effort to shift prescriptions; 2025 R&D/SG&A spend exceeded revenues.
Its path to Star requires broad US insurer formulary placement and rapid patient adoption; failure to secure coverage or scale could see it fade despite 2025 growth.
Wainua
Wainua, AstraZeneca’s recent launch for ATTRv-polyneuropathy, shows strong early uptake but holds a low global market share versus incumbents; peak sales for the ATTR class reached about $1.2bn in 2024, and Wainua’s 2025 H1 net sales were reported at ~$85m as rollout continues.
It sits as a Question Mark: high growth potential in a therapy area growing ~12% CAGR, AstraZeneca is funding aggressive commercial expansion and additional Phase 3 trials to broaden labeling and access.
If Wainua can displace incumbents through label expansion and capture ~20–25% market share by 2027, it could become a Star with projected peak sales of $400–600m; success depends on trial readouts, payer uptake, and supply scaling.
AZD5004 (Oral GLP-1)
AZD5004 is AstraZeneca’s investigational oral GLP-1 for weight management, a market that grew ~40% CAGR 2020–25 to about $70B in 2025, where AZ has zero share.
AZ spent $4.5B on a dedicated metabolic facility in 2025, a massive cash outlay tied to AZD5004 and siblings.
This is a high-stakes Question Mark: successful trials could secure multi-billion revenue, but FYR&D and launch costs plus competition from Novo Nordisk and Eli Lilly make ROI uncertain.
Datroway
Datroway is a TROP2-directed antibody-drug conjugate (ADC) with regulatory submissions in late 2025 for lung and breast cancer; projected global sales of $5.9 billion by 2030 but currently zero commercial share pending launch and reimbursement.
It draws heavy R&D spend and needs a high-intensity promotional push to displace established therapies; AstraZeneca treats it as a high-potential Question Mark to drive future oncology growth.
- Regulatory submissions: late 2025
- Projected 2030 sales: $5.9B
- Current market share: 0%
- Key needs: R&D funding, strong promotion, reimbursement wins
Saphnelo
Saphnelo, AstraZeneca’s first-in-class systemic lupus erythematosus (SLE) therapy, grew 45% in 2025 to roughly $310 million in sales but still holds a low single-digit share of the $18 billion immunology market, making it a Question Mark in the BCG matrix.
It sits in a high-growth segment but faces penetration limits from lupus complexity, specialist prescribing, and payer access; AZ is funding subcutaneous formulation trials and launches in LATAM and APAC to raise uptake.
If subcutaneous delivery and new geography rollouts lift market share above ~10–15% within 2–3 years, Saphnelo could become a Star; failure leaves it a niche asset with constrained returns.
- 2025 sales ≈ $310M (45% YoY growth)
- Immunology market size ≈ $18B (2025)
- Target share to reach Star ≈ 10–15% within 2–3 years
- Key levers: subcutaneous form, LATAM/APAC launches, payer access
Question Marks: High upside drugs need R&D, payers and scale to avoid becoming sinks
Question Marks: Airsupra, Wainua, AZD5004, Datroway and Saphnelo show strong growth or potential but low current share; each needs heavy R&D, payer wins, and commercial scale to become Stars—failure keeps them as cash sinks or niche assets.
| Asset | 2025 sales | Market | Key need |
|---|---|---|---|
| Airsupra | double digit growth | $50B US resp. | formulary |
| Wainua | $85M H1 | $1.2B ATTR | label/payer |
| AZD5004 | 0 | $70B obesity | trial/scale |
| Datroway | 0 | oncology | approval/reimb |
| Saphnelo | $310M | $18B immuno. | formulation/geo |